The Pharmacokinetics, Efficacy, Safety, And Ease Of Use Of A Novel Portable Metered-dose Cannabis Inhaler In Patients With Chronic Neuropathic Pain: A Phase 1a Study

Pain (Neuropathies, in general) Pain (Chronic Non-Malignant)

Key Findings

Chronic neuropathic pain is often refractory to standard pharmacological treatments. A significant 45% reduction in pain intensity was noted 20 minutes post inhalation (P = .001), turning back to baseline within 90 minutes. Tolerable, lightheadedness, lasting 15-30 minutes and requiring no intervention, was the only reported adverse event.

Information and Links


Link: The Pharmacokinetics, Efficacy, Safety, And Ease Of Use Of A Novel Portable Metered-dose Cannabis Inhaler In Patients With Chronic Neuropathic Pain: A Phase 1a Study

Year: 2014

DOI: 10.3109/15360288.2014.941130


Ratings

(How Ratings Work)

Pain (Neuropathies, in general) — 4


Probability toward demonstrable efficacy of cannabis for treatment of Pain (Neuropathies, in general) according to the results found in this study.

Pain (Chronic Non-Malignant) — 4


Probability toward demonstrable efficacy of cannabis for treatment of Pain (Chronic Non-Malignant) according to the results found in this study.

Drugs Used

In a single-dose, open-label study, patients inhaled a single 15.1 ± 0.1 mg dose of cannabis using the Syqe Inhaler device.